Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High serum proteinase-3 levels predict poor progression-free survival and lower efficacy of bevacizumab in metastatic colorectal cancer.
Furuya K, Nakajima M, Tsunedomi R, Nakagami Y, Xu M, Matsui H, Tokumitsu Y, Shindo Y, Watanabe Y, Tomochika S, Maeda N, Iida M, Suzuki N, Takeda S, Hazama S, Ioka T, Hoshii Y, Ueno T, Nagano H. Furuya K, et al. Among authors: tomochika s. BMC Cancer. 2024 Feb 2;24(1):165. doi: 10.1186/s12885-024-11924-4. BMC Cancer. 2024. PMID: 38308214 Free PMC article.
IL-6 Levels Correlate with Prognosis and Immunosuppressive Stromal Cells in Patients with Colorectal Cancer.
Yamamoto T, Tsunedomi R, Nakajima M, Suzuki N, Yoshida S, Tomochika S, Xu M, Nakagami Y, Matsui H, Tokumitsu Y, Shindo Y, Watanabe Y, Iida M, Takeda S, Hazama S, Tanabe T, Ioka T, Hoshii Y, Kiyota A, Takizawa H, Kawakami Y, Ueno T, Nagano H. Yamamoto T, et al. Among authors: tomochika s. Ann Surg Oncol. 2023 Aug;30(8):5267-5277. doi: 10.1245/s10434-023-13527-y. Epub 2023 May 24. Ann Surg Oncol. 2023. PMID: 37222942
Serum CCL7 Is a Novel Prognostic Biomarker of Metastatic Colorectal Cancer.
Chidimatsu H, Tsunedomi R, Nakagami Y, Xu M, Nakajima M, Nakashima-Nakasuga C, Tomochika S, Yoshida S, Suzuki N, Watanabe Y, Matsui H, Shindo Y, Tokumitsu Y, Iida M, Takeda S, Ioka T, Ueno T, Tanabe T, Hoshii Y, Hazama S, Nagano H. Chidimatsu H, et al. Among authors: tomochika s. Anticancer Res. 2023 Jan;43(1):105-114. doi: 10.21873/anticanres.16139. Anticancer Res. 2023. PMID: 36585204
CD4 and FOXP3 as predictive markers for the recurrence of T3/T4a stage II colorectal cancer: applying a novel discrete Bayes decision rule.
Nakagami Y, Hazama S, Suzuki N, Yoshida S, Tomochika S, Matsui H, Shindo Y, Tokumitsu Y, Matsukuma S, Watanabe Y, Iida M, Tsunedomi R, Takeda S, Fujita T, Kawakami Y, Ogihara H, Hamamoto Y, Ioka T, Tanabe T, Ueno T, Nagano H. Nakagami Y, et al. Among authors: tomochika s. BMC Cancer. 2022 Oct 18;22(1):1071. doi: 10.1186/s12885-022-10181-7. BMC Cancer. 2022. PMID: 36253752 Free PMC article.
[Tumor Immunogenicity and Immune Checkpoint Inhibitors].
Nakajima M, Tsunedomi R, Shindo Y, Tokumitsu Y, Matsui H, Watanabe Y, Tomochika S, Yoshida S, Iida M, Suzuki N, Takeda S, Ioka T, Hazama S, Nagano H. Nakajima M, et al. Among authors: tomochika s. Gan To Kagaku Ryoho. 2022 Sep;49(9):922-927. Gan To Kagaku Ryoho. 2022. PMID: 36156006 Review. Japanese.
62 results